Encompass Health (NYSE:EHC) Upgraded at StockNews.com

StockNews.com upgraded shares of Encompass Health (NYSE:EHC) from a hold rating to a buy rating in a report issued on Saturday.

Several other equities analysts have also recently issued reports on EHC. Barclays boosted their price target on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. KeyCorp boosted their price target on Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Truist Financial reissued a “buy” rating and set a $116.00 price target (up previously from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Finally, William Blair restated an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $107.67.

Encompass Health Stock Up 0.8 %

Encompass Health stock opened at $100.91 on Friday. Encompass Health has a 1-year low of $73.02 and a 1-year high of $104.55. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The stock has a market cap of $10.17 billion, a PE ratio of 22.62, a P/E/G ratio of 1.18 and a beta of 0.90. The stock’s fifty day moving average is $95.95 and its two-hundred day moving average is $95.62.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. On average, sell-side analysts expect that Encompass Health will post 4.76 EPS for the current fiscal year.

Insider Buying and Selling at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This represents a 6.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.10% of the stock is currently owned by insiders.

Institutional Trading of Encompass Health

A number of institutional investors and hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Encompass Health by 18.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 367,598 shares of the company’s stock worth $33,948,000 after buying an additional 57,130 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Encompass Health by 44.5% during the 4th quarter. Woodline Partners LP now owns 184,473 shares of the company’s stock worth $17,036,000 after buying an additional 56,817 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Encompass Health by 599.0% during the 4th quarter. Squarepoint Ops LLC now owns 127,204 shares of the company’s stock worth $11,747,000 after buying an additional 109,007 shares during the last quarter. Twinbeech Capital LP purchased a new stake in Encompass Health during the 4th quarter worth $3,893,000. Finally, Two Sigma Advisers LP boosted its position in Encompass Health by 136.3% during the 4th quarter. Two Sigma Advisers LP now owns 63,800 shares of the company’s stock worth $5,892,000 after purchasing an additional 36,800 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.